


## PHARMACEUTICAL 2021

# Evolus Inc. Rank 297 of 409





# RealRate

#### PHARMACEUTICAL 2021

## Evolus Inc. Rank 297 of 409



The relative strengths and weaknesses of Evolus Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evolus Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 145% points. The greatest weakness of Evolus Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 140% points.

The company's Economic Capital Ratio, given in the ranking table, is -302%, being 52% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	127,612
Cost of Goods Sold	18,299
Intangible Assets	76,505
Liabilities, Current	180,248
Liabilities, Non-Current	3,147
Other Assets	3,654
Other Compr. Net Income	-6.0
Other Expenses	91,474
Other Liabilities	98,631
Other Net Income	-9,868
Property and Equipment	1,297
Research and Development	1,722
Revenues	56,540
Selling, General and Administrative Expense	98,190

Output Variable	Value in 1000 USD
Assets	209,068
Liabilities	282,026
Expenses	209,685
Stockholders Equity	-72,958
Net Income	-163,013
Comprehensive Net Income	-163,016
Economic Capital Ratio	-302%

